Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study aims to establish a tolerable dose level and regimen of RAD001 in combination with
cisplatin and etoposide (standard-of-care chemotherapy) in patients with extensive stage
small-cell lung cancer (SCLC) who have not previously been treated with systemic
chemotherapy.